Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) – Research analysts at SunTrust Banks reduced their FY2017 EPS estimates for Conatus Pharmaceuticals in a research note issued to investors on Tuesday. SunTrust Banks analyst J. Boris now forecasts that the biotechnology company will earn ($0.60) per share for the year, down from their previous estimate of ($0.47). SunTrust Banks also issued estimates for Conatus Pharmaceuticals’ Q4 2017 earnings at ($0.14) EPS, FY2018 earnings at $1.73 EPS, FY2019 earnings at $3.91 EPS, FY2020 earnings at $3.67 EPS and FY2021 earnings at $2.45 EPS.

Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.08). Conatus Pharmaceuticals had a negative return on equity of 83.02% and a negative net margin of 80.98%. The business had revenue of $9.57 million during the quarter, compared to analysts’ expectations of $16.06 million. During the same period in the prior year, the firm posted ($0.31) EPS.

COPYRIGHT VIOLATION NOTICE: “Conatus Pharmaceuticals Inc. (CNAT) Forecasted to Post FY2017 Earnings of ($0.60) Per Share” was reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.watchlistnews.com/conatus-pharmaceuticals-inc-cnat-forecasted-to-post-fy2017-earnings-of-0-60-per-share/1695189.html.

Several other research firms have also recently weighed in on CNAT. Zacks Investment Research raised Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. Stifel Nicolaus restated a “buy” rating and issued a $10.00 target price on shares of Conatus Pharmaceuticals in a research note on Thursday, August 3rd. Seaport Global Securities restated a “buy” rating and issued a $16.00 target price on shares of Conatus Pharmaceuticals in a research note on Friday, October 6th. Finally, HC Wainwright restated a “buy” rating and issued a $17.00 target price (down from $18.00) on shares of Conatus Pharmaceuticals in a research note on Thursday, November 2nd. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $16.00.

Conatus Pharmaceuticals (NASDAQ:CNAT) opened at $4.22 on Thursday. The company has a quick ratio of 2.77, a current ratio of 2.69 and a debt-to-equity ratio of 0.41. Conatus Pharmaceuticals has a 1 year low of $1.73 and a 1 year high of $9.40.

Large investors have recently added to or reduced their stakes in the stock. Voya Investment Management LLC bought a new position in Conatus Pharmaceuticals in the 2nd quarter worth about $101,000. Bank of Montreal Can bought a new position in Conatus Pharmaceuticals in the 2nd quarter worth about $109,000. Wells Fargo & Company MN increased its stake in Conatus Pharmaceuticals by 3,098.0% in the 3rd quarter. Wells Fargo & Company MN now owns 19,188 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 18,588 shares during the last quarter. FNY Partners Fund LP increased its stake in Conatus Pharmaceuticals by 98.0% in the 2nd quarter. FNY Partners Fund LP now owns 19,800 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 9,800 shares during the last quarter. Finally, State of Wisconsin Investment Board bought a new position in Conatus Pharmaceuticals in the 2nd quarter worth about $115,000. Institutional investors own 33.04% of the company’s stock.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Earnings History and Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.